Rafferty Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.7M Buy
50,553
+5,522
+12% +$1.88M 0.07% 161
2025
Q4
$17.9M Buy
45,031
+27,880
+163% +$12.3M 0.06% 170
2025
Q3
$7.82M Sell
17,151
-15,045
-47% -$6.13M 0.03% 334
2025
Q2
$10.5M Sell
32,196
-12,389
-28% -$3.43M 0.03% 260
2025
Q1
$12M Sell
44,585
-8,232
-16% -$2.12M 0.05% 226
2024
Q4
$12.4M Sell
52,817
-11,014
-17% -$2.9M 0.04% 249
2024
Q3
$17.6M Sell
63,831
-17,279
-21% -$4.5M 0.06% 170
2024
Q2
$19.7M Buy
81,110
+19,904
+33% +$3.14M 0.07% 146
2024
Q1
$9.15M Buy
61,206
+8,398
+16% +$1.4M 0.03% 295
2023
Q4
$10.1M Buy
52,808
+8,640
+20% +$1.47M 0.04% 276
2023
Q3
$7.82M Buy
44,168
+615
+1% +$117K 0.05% 290
2023
Q2
$8.27M Buy
43,553
+5,362
+14% +$1.06M 0.05% 257
2023
Q1
$7.65M Buy
38,191
+1,888
+5% +$397K 0.05% 256
2022
Q4
$8.63M Buy
36,303
+3,411
+10% +$728K 0.07% 229
2022
Q3
$6.58M Buy
32,892
+1,702
+5% +$325K 0.07% 244
2022
Q2
$4.55M Sell
31,190
-5,845
-16% -$829K 0.04% 295
2022
Q1
$6.05M Buy
37,035
+5,090
+16% +$775K 0.04% 326
2021
Q4
$5.42M Buy
31,945
+15,515
+94% +$2.88M 0.03% 360
2021
Q3
$3.1M Buy
16,430
+621
+4% +$116K 0.02% 457
2021
Q2
$2.68M Sell
15,809
-7,619
-33% -$1.12M 0.02% 549
2021
Q1
$3.31M Buy
23,428
+16,239
+226% +$2.44M 0.02% 424
2020
Q4
$934K Sell
7,189
-9,017
-56% -$1.2M 0.01% 520
2020
Q3
$2.36M Buy
16,206
+6,263
+63% +$890K 0.03% 368
2020
Q2
$1.47M Buy
9,943
+5,863
+144% +$790K 0.02% 434
2020
Q1
$444K Sell
4,080
-29,417
-88% -$3.4M 0.02% 357
2019
Q4
$3.86M Sell
33,497
-44,138
-57% -$4.4M 0.06% 172
2019
Q3
$6.24M Buy
77,635
+6,858
+10% +$543K 0.1% 121
2019
Q2
$5.14M Buy
70,777
+11,052
+19% +$848K 0.09% 160
2019
Q1
$5.58M Buy
+59,725
New +$5M 0.09% 120

Other funds holding ALNY